PRESS RELEASE Statement due to:Andrew W.

Theseeffortswill also help alleviate the $51 billion in annual national healthcare costs associated with high blood circulation pressure. We will continue our strong commitment toimproving the fitness of the nationby supporting attempts and advocating for guidelines that help reduce the responsibility of preventable illnesses and reduce health care costs.. PRESS RELEASE Statement due to:Andrew W. Gurman, M.D., President-elect, American Medical Association As part of the AMA’s long-standing commitment to improving the health of the nation, we continue steadily to focus our attempts on identifying the best ways to prevent the chronic diseases that have the biggest effect on public health and put a fiscal stress on our health care system.and Vista Therapeutics, Inc. Announced today a strategic relationship to build up Nano Biosensors for ActiveCare’s services and products to be used by the elderly. Vista Therapeutics specializes in developing leading nanotechnology. And Harvard University, Vista is developing and marketing nanowire-structured biosensors that detect and will take measurements of more than 250 indicators or markers. Vista Therapeutics has some of the world’s foremost scientists in nanotechnologies, including Spencer Farr, PhD, its Chairman and CEO. Farr was a faculty member at Harvard and MIT and has been an innovator in the toxicology and drug development industry. Lieber happens to be a professor at Harvard’s Section of Chemistry and Chemical Biology and is broadly kept as the foremost pioneer in the development of nanowires, with the demonstration of applications of those materials in nanoelectronics jointly, nanocomputing, biological and chemical sensing, nanophotonics and neurobiology.